TNGX Relative Valuation
TNGX's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, TNGX is overvalued; if below, it's undervalued.
Historical Valuation
Tango Therapeutics Inc (TNGX) is now in the Fair zone, suggesting that its current forward PS ratio of 0.00 is considered Fairly compared with the five-year average of -5.95. The fair price of Tango Therapeutics Inc (TNGX) is between to according to relative valuation methord.
Relative Value
Fair Zone
-
Current Price：10.12
Fair
-7.76
PE
1Y
3Y
5Y
Trailing
Forward
-6.30
EV/EBITDA
Tango Therapeutics Inc. (TNGX) has a current EV/EBITDA of -6.30. The 5-year average EV/EBITDA is -2.50. The thresholds are as follows: Strongly Undervalued below -8.95, Undervalued between -8.95 and -5.72, Fairly Valued between 0.72 and -5.72, Overvalued between 0.72 and 3.95, and Strongly Overvalued above 3.95. The current Forward EV/EBITDA of -6.30 falls within the Undervalued range.
-6.63
EV/EBIT
Tango Therapeutics Inc. (TNGX) has a current EV/EBIT of -6.63. The 5-year average EV/EBIT is -2.82. The thresholds are as follows: Strongly Undervalued below -8.82, Undervalued between -8.82 and -5.82, Fairly Valued between 0.19 and -5.82, Overvalued between 0.19 and 3.19, and Strongly Overvalued above 3.19. The current Forward EV/EBIT of -6.63 falls within the Undervalued range.
2316.66
PS
Tango Therapeutics Inc. (TNGX) has a current PS of 2316.66. The 5-year average PS is 98.99. The thresholds are as follows: Strongly Undervalued below -647.81, Undervalued between -647.81 and -274.41, Fairly Valued between 472.39 and -274.41, Overvalued between 472.39 and 845.80, and Strongly Overvalued above 845.80. The current Forward PS of 2316.66 falls within the Strongly Overvalued range.
-8.61
P/OCF
Tango Therapeutics Inc. (TNGX) has a current P/OCF of -8.61. The 5-year average P/OCF is -3.16. The thresholds are as follows: Strongly Undervalued below -9.12, Undervalued between -9.12 and -6.14, Fairly Valued between -0.18 and -6.14, Overvalued between -0.18 and 2.80, and Strongly Overvalued above 2.80. The current Forward P/OCF of -8.61 falls within the Undervalued range.
20.06
P/FCF
Tango Therapeutics Inc. (TNGX) has a current P/FCF of 20.06. The 5-year average P/FCF is -1.77. The thresholds are as follows: Strongly Undervalued below -9.82, Undervalued between -9.82 and -5.79, Fairly Valued between 2.26 and -5.79, Overvalued between 2.26 and 6.28, and Strongly Overvalued above 6.28. The current Forward P/FCF of 20.06 falls within the Strongly Overvalued range.
Tango Therapeutics Inc (TNGX) has a current Price-to-Book (P/B) ratio of 6.67. Compared to its 3-year average P/B ratio of 3.01 , the current P/B ratio is approximately 121.29% higher. Relative to its 5-year average P/B ratio of 2.29, the current P/B ratio is about 190.98% higher. Tango Therapeutics Inc (TNGX) has a Forward Free Cash Flow (FCF) yield of approximately 0.00%. Compared to its 3-year average FCF yield of -26.67%, the current FCF yield is approximately -100.00% lower. Relative to its 5-year average FCF yield of -22.35% , the current FCF yield is about -100.00% lower.
6.90
P/B
Median3y
3.01
Median5y
2.29
-11.39
FCF Yield
Median3y
-26.67
Median5y
-22.35
Competitors Valuation Multiple
The average P/S ratio for TNGX's competitors is 0.00, providing a benchmark for relative valuation. Tango Therapeutics Inc Corp (TNGX) exhibits a P/S ratio of , which is NaN% above the industry average. Given its robust revenue growth of 363.61%, this premium appears sustainable.
P/S
P/E
EV/EBITDA
EV/EBIT
P/S
Revenue Growth
Market Cap
Performance Decomposition
1Y
3Y
5Y
Market capitalization of TNGX increased by 220.39% over the past 1 year. The primary factor behind the change was an increase in Revenue Growth from 11.61M to 53.81M.
The secondary factor is the P/E Change, contributed -31.47%to the performance.
Overall, the performance of TNGX in the past 1 year is driven by Revenue Growth. Which is more sustainable.
People Also Watch
FAQ
Is Tango Therapeutics Inc (TNGX) currently overvalued or undervalued?
What is Tango Therapeutics Inc (TNGX) fair value?
How does TNGX's valuation metrics compare to the industry average?
What is the current P/B ratio for Tango Therapeutics Inc (TNGX) as of Dec 05 2025?
What is the current FCF Yield for Tango Therapeutics Inc (TNGX) as of Dec 05 2025?
What is the current Forward P/E ratio for Tango Therapeutics Inc (TNGX) as of Dec 05 2025?